Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25758856 | 0.76 | PI4KA (0.56) | CYP1A2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24659480 | 0.75 | CYP1A2 (0.39) | CYP1A2CYP17A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL156688 | 0.75 | PI4KA (0.61) | CYP1A2CYP17A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29773082 | 0.75 | PI4KA (0.61) | CYP1A2CYP17A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL26298375 | 0.67 | CYP1A2 (0.55) | CYP1A2CYP17A1TSHRCYP3A4CYP2C9 | |
| SCHEMBL7317167 | 0.66 | HPGD (0.43) | CYP1A2CYP17A1HPGD | |
| SCHEMBL21126169 | 0.64 | PNP (0.45) | CYP1A2ALDH1A1XDHKDM4E | |
| SCHEMBL22971112 | 0.62 | PI4KA (0.57) | CYP1A2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21636970 | 0.62 | ALDH1A1 (0.63) | CYP1A2CYP17A1TSHRCYP3A4CYP2C9 | |
| SCHEMBL22521559 | 0.62 | CYP1A2 (0.47) | CYP1A2CYP17A1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230383296-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220056451-A1 | HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE | ALIGOS THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20210317457-A1 | ANTISENSE OLIGONUCLEOTIDE (ASO) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20200385735-A1 | MODIFIED GAPMER OLIGONUCLEOTIDES AND METHODS OF USE | ALIGOS THERAPEUTICS, INC. (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | ALIGOS THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056451-A1 | HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE | HAVCR2, POLRMT, DCLRE1B | CYP1A2 4621/4885CYP17A1 3865/4885PI4KA 3367/4885 |
| US-20210317457-A1 | ANTISENSE OLIGONUCLEOTIDE (ASO) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES | ACE2, SARS1, ACE | CYP1A2 4432/4885CYP17A1 2471/4885PI4KA 3675/4885 |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | STING1, CGAS, IRF3 | CYP1A2 4751/4885CYP17A1 3853/4885PI4KA 2127/4885 |
| US-20200385735-A1 | MODIFIED GAPMER OLIGONUCLEOTIDES AND METHODS OF USE | HAVCR2, ADAR, RNMT | CYP1A2 4775/4885CYP17A1 4712/4885PI4KA 1783/4885 |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | CYP1A2 4751/4885CYP17A1 3853/4885PI4KA 2127/4885 |
| US-20230383296-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | GJA1, GAP43, GJB2 | CYP1A2 4875/4885CYP17A1 4647/4885PI4KA 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.